Akari Therapeutics Plc (AKTX)

0.4501 +0.04 (+9.78%) USD  |  NASDAQ  |  Dec 12, 11:17
More

Akari Therapeutics Research and Development Expense (Quarterly): 0.2475M for Sept. 30, 2025

Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for AKTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
DBV Technologies SA 26.82M
Cellectis SA 19.34M
Biodexa Pharmaceuticals Plc --
NuCana Plc 2.928M
Autolus Therapeutics Plc 27.72M